샘플 요청 목록

 카트 문의
시장보고서
상품코드
1533759

세계의 만성신부전 치료제 시장

Chronic Renal Failure Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 178 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 만성신부전 치료제 시장은 2030년까지 229억 달러에 이를 것으로 예상

2023년에 201억 달러로 평가된 세계의 만성신부전 치료제 시장은 분석 기간 2023년부터 2030년까지 CAGR 1.9%로 성장할 전망이며, 2030년에는 229억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 강압제는 CAGR 1.7%로 성장을 지속하고, 분석 기간 종료 시에는 163억 달러에 달할 것으로 예측됩니다. 항빈혈제 부문은 분석 기간 동안 CAGR 2.7%의 성장이 예상됩니다.

미국 시장은 55억 달러, 중국은 CAGR 4.0%로 성장할 것으로 예측

미국의 만성신부전 치료제 시장은 2023년 55억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 44억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023년부터 2030년까지 CAGR은 4.0%로 전망됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 0.4%와 1.4%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 약 0.9%로 성장할 것으로 예측됩니다.

세계의 만성신부전 치료제 시장-주요 동향 및 촉진요인 요약

만성신부전은 만성 신장 질환(CKD)으로도 알려져 있으며, 시간이 지남에 따라 신장 기능이 점차 감소하는 것을 특징으로하는 진행성 질환입니다. 이 쇠약성 질환은 세계 수백만 명이 앓고 있으며 심혈관 질환, 빈혈, 뼈 장애와 같은 심각한 건강 합병증을 유발합니다. CKD 치료의 첫 번째 목표는 질병의 진행을 늦추고, 증상을 관리하고, 환자의 삶의 질을 향상시키는 것입니다. 초기 단계의 치료에는 다이어트, 운동 요법, 혈압 관리 등 생활 습관의 개선이 포함되는 경우가 많습니다. 안지오텐신 전환 효소(ACE) 억제제 및 안지오텐신 II 수용체 길항제(ARB)와 같은 약물은 고혈압을 조절하고 신장 기능을 유지하는 데 도움이되는 단백질 소변을 줄이기 위해 일반적으로 처방됩니다. 또한 고혈당은 신장 장애를 악화시키기 때문에 CKD 환자에서는 당뇨병 관리가 중요합니다.

CKD가 진행됨에 따라 치료 전략은 더욱 복잡하고 집중적입니다. 빈혈 관리에는 적혈구 생산을 촉진하고 피로를 줄이기 위해 적혈구 조혈 자극 인자 제제(ESA)와 철 보충제를 사용하는 경우가 많습니다. 미네랄 및 뼈 장애 관리에는 미네랄 균형과 뼈 건강을 유지하기 위해 인산염 바인더, 비타민 D 유사체 및 칼시 메틱을 사용합니다. 말기 신부전(ESRD)에 도달한 환자에게는 투석과 신장 이식과 같은 신장 대체요법이 필요합니다. 혈액 투석과 복막 투석은 신장의 여과 기능을 수행하는 생명 유지를 위한 치료법인 반면, 이식은 치료 가능성을 제공하지만 장기 거부 반응을 방지하기 위해 평생 면역 억제가 필요합니다.

만성신부전 치료제 시장의 성장은 당뇨병, 고혈압, 고령화율 증가로 인한 CKD 유병률 증가 등 여러 요인에 의해 견인되고 있습니다. 진단 도구의 기술적 진보로 CKD의 조기 발견이 개선되어 시기 적절한 개입과 더 나은 질병 관리가 가능해졌습니다. 또한 적극적인 건강 관리와 정기적인 검진에 대한 소비자의 행동도 CKD의 조기 진단과 치료에 기여하고 있습니다. 게다가 제약회사에 의한 연구개발에 대한 다액의 투자에 의해 신규 치료제이나 기존약의 개량형 제제의 도입이 행해지게 되었습니다. 규제 당국의 지원과 유리한 상환 정책은 첨단 CKD 치료제의 채택을 더욱 촉진하고 있습니다. 특히 신흥국에서는 헬스케어 인프라가 정비되어 CKD 치료제과 신장 대체요법에 대한 접근이 증가하고 있습니다. 이러한 요인들이 결합되어 환자의 예후를 개선하고 이 만성 질환을 앓고 있는 사람들의 수명을 연장시키는 것을 목표로 하는 만성신부전 치료제 시장은 역동적으로 성장하고 있습니다.

조사 대상 기업 예(전 37건)

  • Akebia Therapeutics, Inc.
  • Amgen, Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc
  • Sanofi SA
  • Siemens Healthineers AG;

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

AJY 24.08.22

Global Chronic Renal Failure Therapeutics Market to Reach US$22.9 Billion by 2030

The global market for Chronic Renal Failure Therapeutics estimated at US$20.1 Billion in the year 2023, is expected to reach US$22.9 Billion by 2030, growing at a CAGR of 1.9% over the analysis period 2023-2030. Antihypertensive Drugs, one of the segments analyzed in the report, is expected to record a 1.7% CAGR and reach US$16.3 Billion by the end of the analysis period. Growth in the Antianemia Drugs segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.5 Billion While China is Forecast to Grow at 4.0% CAGR

The Chronic Renal Failure Therapeutics market in the U.S. is estimated at US$5.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2030 trailing a CAGR of 4.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.4% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.9% CAGR.

Global Chronic Renal Failure Therapeutics Market - Key Trends and Drivers Summarized

Chronic renal failure, also known as chronic kidney disease (CKD), is a progressive condition characterized by the gradual loss of kidney function over time. This debilitating disease affects millions worldwide, leading to serious health complications such as cardiovascular disease, anemia, and bone disorders. The primary goal of therapeutics for CKD is to slow disease progression, manage symptoms, and improve the quality of life for patients. Early-stage treatments often include lifestyle modifications such as dietary changes, exercise, and blood pressure control. Medications like angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are commonly prescribed to control hypertension and reduce proteinuria, which helps to preserve kidney function. Additionally, diabetes management is crucial in CKD patients, as hyperglycemia can exacerbate kidney damage.

As CKD progresses to more advanced stages, therapeutic strategies become more complex and intensive. Anemia management often involves the use of erythropoiesis-stimulating agents (ESAs) and iron supplements to boost red blood cell production and alleviate fatigue. Mineral and bone disorder management is addressed through phosphate binders, vitamin D analogs, and calcimimetics to maintain mineral balance and bone health. For patients reaching end-stage renal disease (ESRD), renal replacement therapies such as dialysis and kidney transplantation become necessary. Hemodialysis and peritoneal dialysis are life-sustaining treatments that perform the filtration functions of the kidneys, while transplantation offers a potential cure but requires lifelong immunosuppression to prevent organ rejection.

The growth in the chronic renal failure therapeutics market is driven by several factors, including the increasing prevalence of CKD due to rising rates of diabetes, hypertension, and aging populations. Technological advancements in diagnostic tools have improved the early detection of CKD, enabling timely intervention and better disease management. Consumer behavior towards proactive health management and regular screenings has also contributed to the early diagnosis and treatment of CKD. Additionally, significant investments in research and development by pharmaceutical companies have led to the introduction of novel therapies and improved formulations of existing drugs. Regulatory support and favorable reimbursement policies have further facilitated the adoption of advanced CKD treatments. The expansion of healthcare infrastructure, particularly in emerging economies, has increased access to CKD therapeutics and renal replacement therapies. These factors collectively ensure a dynamic and growing market for chronic renal failure therapeutics, aiming to enhance patient outcomes and extend the lives of those affected by this chronic condition.

Select Competitors (Total 37 Featured) -

  • Akebia Therapeutics, Inc.
  • Amgen, Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc
  • Sanofi SA
  • Siemens Healthineers AG;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Chronic Renal Failure Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Kidney Failure Associated With Rising Global Prevalence of Diabetes and Hypertension Spurs Demand for Renal Failure Therapeutics
    • Advances in Dialysis Technology Enhance Treatment Efficacy and Patient Comfort
    • Development of Novel Pharmacologic Treatments to Delay Kidney Disease Progression
    • Growing Focus on Preventive Healthcare Measures & Expansion of Renal Disease Awareness Programs Bolster Early Intervention Efforts & Diagnosis Rates
    • Impact of Aging Population on Healthcare Systems and Renal Therapy Needs
    • Advancements in Gene Therapy and Stem Cell Research Open New Treatment Avenues
    • Global Health Initiatives Aimed at Improving Access to Renal Care to Benefit Market Growth
    • Review of the Economic Burden of Chronic Renal Failure
    • Innovations in Kidney Transplant Procedures and Immunosuppressive Therapies
    • Shift Towards Personalized Medicine in Managing Chronic Kidney Disease
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Chronic Renal Failure Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Chronic Renal Failure Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Chronic Renal Failure Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antihypertensive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antihypertensive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antihypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antianemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antianemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antianemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • CHINA
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Chronic Renal Failure Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Chronic Renal Failure Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Chronic Renal Failure Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Chronic Renal Failure Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • INDIA
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Chronic Renal Failure Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Chronic Renal Failure Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Chronic Renal Failure Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Chronic Renal Failure Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제